Forty percent of patients in the trial survived at least 15 months, compared to 20 percent of the more general population, Von Hoff stated. The greatest benefits were seen in breast cancer.
The targets and therapies chosen were different from what the patients' doctors said they would have tried.
"We feel that this can help people who have progressed on everything else," Von Hoff said.
A second study from Italian researchers found that specific genetic mutations in patients with advanced colorectal cancer could indicate that the tumor will not respond to two monoclonal antibodies, Erbitux (cetuximab) and Vectibix (panitumumab).
Two studies also to be presented at the meeting focused on the brain tumors known as glioblastomas.
One from researchers at the University of Pennsylvania indicated that an imaging technique known as magnetic resonance perfusion-weighted imaging may be able to identify genetic mutations which could then help guide treatment choices. With further validation, these findings may result in use of the procedure in clinical trials and, further down the line, actual practice, said Dr. Deepa Subramaniam, director of the brain tumor center at Lombardi Comprehensive Cancer Center, Georgetown University, in Washington, D.C.
The second glioblastoma study, from doctors at Massachusetts General Hospital in Boston, identified a biomarker which could select out patients with brain tumors that would respond better to cediranib, a drug targeting the anti-vascular endothelial growth factor, which is in the research pipeline.
"This sounds very exciting and is going to become a standard marker in clinical trials," Subramaniam said.
More information
The U.S. National Cancer Institute has more on tumor markers.
'/>"/>
| Copyright©2009 ScoutNews,LLC. All rights reserved |